(VIANEWS) – The NASDAQ opens in less than two hours and DexCom‘s pre-market value is already 4.23% up.
DexCom’s last close was $130.10, 3.01% under its 52-week high of $134.14.
The last session, NASDAQ finished with DexCom (DXCM) sliding 0.67% to $130.10. NASDAQ fell 0.68% to $13,689.57, following the last session’s downward trend on what was a somewhat bearish trend exchanging session.
About DexCom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, DexCom has a trailing twelve months EPS of $0.7.
PE Ratio
DexCom has a trailing twelve months price to earnings ratio of 185.86. Meaning, the purchaser of the share is investing $185.86 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.23%.
Moving Average
DexCom’s worth is higher than its 50-day moving average of $120.26 and way higher than its 200-day moving average of $110.49.
More news about DexCom (DXCM).
